Understanding how immune checkpoint inhibitors interact with other medications
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
This study is looking at how cancer treatments called immune checkpoint inhibitors might interact with other medications you’re taking, to help make sure they work safely and effectively together.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10896252 on NIH RePORTER |
What this research studies
This research investigates how immune checkpoint inhibitors, which are used in cancer treatment, may interact with other medications that patients are taking. It focuses on the role of pro-inflammatory cytokines produced during treatment, which can affect liver enzymes responsible for drug metabolism. By identifying potential drug-drug interactions, the research aims to reduce adverse events and improve the safety and effectiveness of checkpoint inhibitor therapies for patients. The approach includes analyzing patient data and conducting assays to discover these interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving immune checkpoint inhibitors who are also taking other medications.
Not a fit: Patients who are not undergoing treatment with immune checkpoint inhibitors or who are not taking any other medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments by minimizing adverse effects associated with immune checkpoint inhibitors.
How similar studies have performed: Previous studies have indicated that drug-drug interactions can significantly impact the safety of cancer therapies, suggesting that this research could build on established findings.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Shugg, Tyler a — Indiana University Indianapolis
- Study coordinator: Shugg, Tyler a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.